American Association for Cancer Research

Table 2

Toxicity for all cycles (worst grade)^a

	1	2	3	4	(% Grades 3–4)
Myalgias	6	9	13 (6)	0	40.6
Ataxia^b	0	0	3	0	9.3
Headache	5	1	0	0
Fatigue	17	2	2	0	6.3
Urinary frequency	1	2	2	0	6.3
Dyspnea	3	3	3	2	15.6
Anemia	3	6	2	0	6.3
Leg weakness	0	0	1	0	3.1
Allergic reaction	0	0	1	0	3.1
GI (N/V)^c	6	4	0	0
Anorexia	7	3	1	0	3.1
Edema/weight gain	0	0	1	0	3.1

	1	2	3	4	(% Grades 3–4)
Myalgias	6	9	13 (6)	0	40.6
Ataxia^b	0	0	3	0	9.3
Headache	5	1	0	0
Fatigue	17	2	2	0	6.3
Urinary frequency	1	2	2	0	6.3
Dyspnea	3	3	3	2	15.6
Anemia	3	6	2	0	6.3
Leg weakness	0	0	1	0	3.1
Allergic reaction	0	0	1	0	3.1
GI (N/V)^c	6	4	0	0
Anorexia	7	3	1	0	3.1
Edema/weight gain	0	0	1	0	3.1

Six of the 13 patients had grade 3 myalgias after three or greater cycles.

Reported ataxia was noted in two, three, and seven cycles.

GI (N/V), Gastrointestinal (Nausea/Vomiting).